A major problem I have is that their population has a prevalence of preeclampsia that is far lower than the general popluation (table 1) and therefore their results are not generalizable. The gen pop has incidence of 5% and hyeprtensives 25% whereas their cohort has incidence of .83 and 4% (of women on beta blockers) respectively. The authors need to address this.
Another major problem is that they don't state what percent of women have gestational or essential hypertension at the outset, and the fact that these conditions are known risk factors for the outcomes-are they controlled for adequately? Why aren't they in table 1 or 2?
The concluding statement-the future treatment of pregnant women with beta blockers should therefore be based primarily on the individual needs of the mother and not the child-is very puzzling.
Need to clearly state that this is an observational study and that it is hypothesis generating, need a trial to validate the hypothesis. Cannot make recommendations based on this study. A major problem I have is that their population has a prevalence of preeclampsia that is far lower than the general popluation (table 1) and therefore their results are not generalizable. The gen pop has incidence of 5% and hyeprtensives 25% whereas their cohort has incidence of .83 and 4% (of women on beta blockers) respectively. The authors need to address this. Response: We appreciate this constructive comment. In the Method section, we explain that we removed 2836 records with pregnancy-induced hypertension from the cohort. We defined pregnancy-induced hypertension as having a first-time redemption of an antihypertensive drug prescription after the twentieth week of gestation, but never before. Assuming these women have gestational hypertension or pre-eclampsia, the prevalence increases to 1.2 % in the general population. An important reason for the low prevalence of pre-eclampsia in our study might be because we used primary discharge diagnoses from hospital admissions. Secondary diagnoses were not used, since these in general are not validated. Pre-eclampsia and eclampsia treated outside hospitals, e.g. in primary practice, were not included in our survey. Our cohort covers an entire nation, and we therefore believe that our primary results are generalizable. Our prevalence of pre-eclampsia was lower than expected due to the mentioned methods. We agree with the reviewer that this should be addressed. Accordingly, changes were made in the following sections of the article: we point out that we obtained primary diagnoses in the method section, p. 5, l 10-13. Changes are made on p. 10, table 1.
Comment
Another major problem is that they don't state what percent of women have gestational or essential hypertension at the outset, and the fact that these conditions are known risk factors for the outcomesare they controlled for adequately? Why aren't they in table 1 or 2? Response: This is an important point. We agree that these are known risk factors for our primary outcomes. Unfortunately we could not adjust our analyses for these conditions, since we only had access to primary discharge diagnoses given at hospitals. We believe that many women receive treatment outside hospitals, e.g. in primary care. Our study focuses on the association between drug redemption and adverse pregnancy outcomes. We do not have access to valid data on maternal essential hypertension, which is regrettably an important limitation. Consequently we have not included rates and percentages on essential hypertension in tables 1 or 2. This limitation is addressed in the discussions section under limitations, p. 18, l. 19 with the sentence: "unfortunately information on diagnoses of essential hypertension was not available, since these are known risk factors for our primary outcomes."
Comment:
The concluding statement-the future treatment of pregnant women with beta blockers should therefore be based primarily on the individual needs of the mother and not the child-is very puzzling. Need to clearly state that this is an observational study and that it is hypothesis generating, need a trial to validate the hypothesis. Cannot make recommendations based on this study. Response:
We agree with the reviewer that recommendations should be based on a trial and not a study with an observational design. Therefore, changes were made in the following sentence: p3, l. 3-4 and p. 19, l. 9-11. On the basis of the reviewers comment we have changed the last section: "The increasing use and uncertainty of effects and possible side effects of treatment with beta-blockers during pregnancy call for further studies to validate our findings.", p. 19, l. 11-13.
Comment: Drug effect bblocker class effect vs. disease effect? This is not answered.
Response: This is indeed a problem with the observational study design. We cannot adjust for treatment and severity of maternal disease, which is added in the Discussion section on p. 18. This section has been expanded with "Consequently we were unable to differentiate between a possible class effect of betablockers and the effect of the underlying maternal disease", p. 18, l. 17.
Comment (minor):
No need to write icd10 codes Response:
We chose to keep icd10 codes in our manuscript in order to ensure that our design is replicable. If reviewer disagrees, we will of course remove all icd10 codes.
Say filling prescription, not redeeming Response:
We thank the reviewer for the comment. We have not replaced the word redeeming with filling, since, according to our understanding, their meaning is not quite the same. Our understanding is, the women redeem the prescription, whereas the pharmacy fills prescriptions. We are of course willing to change the formulation if we have misunderstood the meaning of the word redeeming. Comment (minor): Don't address women who are on 2 or 3 different antihypertensives, or on other meds as confounders.
Response: Women redeeming prescriptions of multiple beta-blockers are mentioned in the results section. However, we did not adjust our analyses for redemption of 2 or 3 beta-blockers. This is not addressed as confounders. Redemption of prescriptions for insulins and analogues, statins and antiobesity preparations were used as a proxy for maternal disease other than hypertension. These are risk factors for the defined outcomes, and accordingly we believe that these adjustments are relevant. 
